Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older.

by Graham R Foster, Tarik Asselah, Sarah Kopecky-Bromberg, Yang Lei, Armen Asatryan, Roger Trinh, Neddie Zadeikis, Federico J Mensa
Published 2019-01-01

Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir.

by Kristi L Berger, Christoph Sarrazin, David R Nelson, Joseph Scherer, Nanshi Sha, Martin Marquis, Alexandra Côté-Martin, Richard Vinisko, Jerry O Stern, Federico J Mensa, George Kukolj
Published 2016-01-01

ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection.

by Tarik Asselah, Stefan Zeuzem, Vicente Soriano, Jean-Pierre Bronowicki, Ansgar W Lohse, Beat Müllhaupt, Marcus Schuchmann, Marc Bourlière, Maria Buti, Stuart K Roberts, Edward J Gane, Jerry O Stern, Florian Voss, Patrick Baum, John-Paul Gallivan, Wulf O Böcher, Federico J Mensa
Published 2015-01-01